Specifically, a set of TOP2A inhibitors were determined as potential chemoprotective drugs in various types of cancer, such as doxorubicin in solid tumors, leukemias and lymphomas [43], Idarubicin in HCC [44], acute myelogenous leukemia, advanced breast cancer, multiple myelom, non-Hodgkin's lymphoma, and other malignancies [45], and etoposide in several malignant tumors [46–50] and metastatic tumors (such as brain metastasis of breast cancer) [51, 52]. Here, TOP2A is linked to non-Hodgkin lymphoma.